Swiss National Bank Sells 518,200 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Swiss National Bank lowered its position in Bausch Health Companies Inc. (NYSE:BHC – Get Rating) by 42.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 699,260 shares of the company’s stock after selling 518,200 shares during the period. Swiss National Bank’s holdings in Bausch Health Companies were worth $4,389,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. National Bank of Canada FI raised its position in Bausch Health Companies by 12,687.5% in the 4th quarter. National Bank of Canada FI now owns 13,136,603 shares of the company’s stock worth $82,497,000 after purchasing an additional 13,033,873 shares during the last quarter. Vanguard Group Inc. raised its position in Bausch Health Companies by 2.0% in the 3rd quarter. Vanguard Group Inc. now owns 10,924,375 shares of the company’s stock worth $75,268,000 after purchasing an additional 219,279 shares during the last quarter. Rubric Capital Management LP bought a new position in Bausch Health Companies in the 3rd quarter worth approximately $22,492,000. Hsbc Holdings PLC raised its position in Bausch Health Companies by 2,700.9% in the 3rd quarter. Hsbc Holdings PLC now owns 3,112,553 shares of the company’s stock worth $22,182,000 after purchasing an additional 3,001,427 shares during the last quarter. Finally, Silver Point Capital L.P. bought a new position in Bausch Health Companies in the 3rd quarter worth approximately $20,498,000. Institutional investors own 66.99% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, StockNews.com assumed coverage on shares of Bausch Health Companies in a report on Thursday. They set a “hold” rating for the company. Five analysts have rated the stock with a hold rating, According to data from MarketBeat, Bausch Health Companies presently has a consensus rating of “Hold” and a consensus price target of $8.67.

Bausch Health Companies Price Performance

Shares of BHC stock opened at $8.30 on Friday. Bausch Health Companies Inc. has a 12-month low of $4.00 and a 12-month high of $10.41. The firm has a market capitalization of $3.00 billion, a price-to-earnings ratio of -8.47, a price-to-earnings-growth ratio of 0.13 and a beta of 0.98. The company has a quick ratio of 0.77, a current ratio of 1.08 and a debt-to-equity ratio of 139.36. The firm has a fifty day moving average of $7.28 and a 200-day moving average of $7.50.

Bausch Health Companies (NYSE:BHC – Get Rating) last announced its quarterly earnings results on Thursday, February 23rd. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.10. Bausch Health Companies had a negative net margin of 4.38% and a positive return on equity of 381.67%. The company had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.12 billion. On average, equities research analysts forecast that Bausch Health Companies Inc. will post 3.34 earnings per share for the current year.

About Bausch Health Companies

(Get Rating)

Bausch Health Cos., Inc engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb.